Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs.
Compound Oclacitinib Maleate Chewable Tablets are a specialized pet skin drug formulated to manage pruritus associated with allergic dermatitis and to control atopic dermatitis in dogs. By combining oclacitinib maleate with prednisolone in a chewable format, this product offers a targeted solution for interrupting inflammatory and itch pathways common in canines with skin allergies. Available in multiple strengths, it supports precise weight‑based dosing for consistent therapeutic results. WERVIC provides this product and offers comprehensive OEM and ODM services, enabling custom formulation, packaging, and branding tailored to partner needs.
Oclacitinib Maleate, Prednisolone
DESCRIPTION
Light brown to brown tablets.
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs.
The dose of Locadermin (Compound Oclacitinib Maleate Chewable Tablet) is 0.4 to 0.6 mg oclacitinib/kg body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy.
|
Weight Range(kg) |
Number of Tablets to be Administered |
||
|
3.6mg Tablets |
5.4mg Tablets |
16mg Tablets |
|
|
3.0～4.4 |
0.5 |
- |
- |
|
4.5～5.9 |
- |
0.5 |
- |
|
6.0～8.9 |
1 |
- |
- |
|
9.0～13.4 |
- |
1 |
- |
|
13.5～19.9 |
- |
- |
0.5 |
|
20.0～26.9 |
- |
2 |
- |
|
27.0～39.9 |
- |
- |
1 |
|
40.0～54.9 |
- |
- |
1.5 |
|
55.0～80.0 |
- |
- |
2 |
Not applicable
Calculated on C15H23N5O2S: (1)3.6mg (2)5.4mg (3)16mg
Preserve in well closed containers.
SHELF LIFE
36 months
1. The product is not for use in dogs less than 12 months of age or less than 3 kg of body weight. It is not for use in breeding dogs, or pregnant or lactating bitches. It is not for use in dogs with serious infections (systemic infections such as pneumonia or generalized fungal infections).
Prednisolone is a potent therapeutic agent influencing the biochemical behavior of most, if not all, tissues of the body. Because this anti-inflammatory steroid manifests little sodium-retaining activity, the usual early sign of cortisone or hydrocortisone overdosage (i.e., increase in body weight due to fluid retention) is not a reliable index of overdosage. Hence, recommended dose levels should not be exceeded, and all animal patients receiving prednisolone should be under close medical supervision. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapid-acting corticosteroid should be considered in unusually stressful situations.
2. Consider the risks and benefits of treatment prior to initiating the product in dogs with a history of recurrent serious infections or recurrent demodicosis or neoplasia.
3. The product modulates the immune system.
4. Dogs receiving the product should be monitored for the development of infections, including demodicosis, and neoplasia.
5. The product can be administered mixed with feed or on an empty stomach.
6. The use of this product has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents.
7. Wash hands immediately after handling the tablets. In case of accidental eye contact, flush immediately with water or saline for at least 15 minutes and then seek medical attention.
8. Keep out of reach of children.
9. For use in dogs only. In case of accidental ingestion, seek medical attention immediately.
24+ years of experience in the animal health industry, with a focus on veterinary drug development and manufacturing
High‑tech R&D capability: over 60% of R&D engineers hold master’s or higher degrees; six provincial and municipal innovation platforms
Proven track record: developed six national Class III new veterinary drugs and multiple provincial high‑tech products
Intelligent manufacturing: four specialized R&D and production bases with smart production control
Full OEM/ODM support: from formula development and packaging design to bulk production, with dedicated order coordination
